BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:The Tock Tick of Senescence - Prof Cleo Bishop\; Barts and The Lon
 don Faculty of Medicine and Dentistry\, Queen Mary University of London
DTSTART:20230418T123000Z
DTEND:20230418T133000Z
UID:TALK197830@talks.cam.ac.uk
CONTACT:Bobbie Claxton
DESCRIPTION:Restraining or slowing ageing hallmarks at the cellular level 
 have been proposed as a route to increased organismal lifespan. Consequent
 ly\, there is great interest in anti-ageing drug discovery. However\, this
  currently requires laborious and lengthy longevity analysis. Here\, we re
 port a novel screening platform for the expedited discovery of compounds t
 hat restrain cellular ageing in vitro and enable extension of in vivo life
 span. For this\, we developed a novel epigenetic clock\, the CellAgeClock\
 , to accurately monitor cellular ageing in adult human primary cells. We f
 ind that the CellAgeClock can detect decelerated passage-based cellular ag
 eing of human primary cells treated with Rapamycin or Trametinib\, well es
 tablished longevity drugs. We then utilise the CellAgeClock as a screening
  tool for the identification of compounds which decelerate cellular ageing
 \, uncovering novel anti-ageing drugs. We demonstrate that delayed cellula
 r ageing in human primary cells treated with anti-ageing compounds is acco
 mpanied by a reduction in senescence and ageing biomarkers. Finally\, we e
 xtend our screening platform in vivo by taking advantage of a specially fo
 rmulated holidic medium for increased drug bioavailability in Drosophilia.
  We show that the novel anti-ageing drugs increase longevity in vivo. In s
 ummary\, our method expands the scope of CpG methylation profiling to accu
 rately and rapidly detecting anti-ageing potential of drugs using human ce
 lls in vitro and in vivo\, providing a novel accelerated discovery platfor
 m to test sought after anti-ageing compounds and geroprotectors.\n\nCleo r
 eceived her PhD in Biological Sciences from University College London in 2
 001. She then spent four years as a MRC Career Development Fellow in the l
 aboratory of Prof. Chris Higgins at the MRC Clinical Sciences Centre (now 
 the London Institute of Medical Sciences)\, Imperial College London\, wher
 e she developed a keen interest in cancer biology. In 2006\, she moved to 
 the Blizard Institute to pursue her interest in senescence and cancer\, sp
 ending four years in the laboratory of Prof. David Beach (FRS). During thi
 s time\, she established our Phenotypic Screening facility\, and has used 
 this technology to discover novel regulators of the ageing and senescence 
 biomarker\, p16. In 2010\, Cleo started her own group\, and in 2022 was pr
 omoted to Professor. Current projects in Cleo’s lab aim to illuminate se
 nescence mechanisms\, understand how cells age\, explore the interplay bet
 ween healthy ageing and cellular rejuvenation\, and target senescence for 
 ageing and cancer therapy. Cleo is also currently Academic Lead for The QM
 UL Phenotypic Screening Facility and MB PhD Programme\, and Research Lead 
 for her Centre.
LOCATION:Kings Hedges Room 
END:VEVENT
END:VCALENDAR